Merus (MRUS) has agreed to give Partner Therapeutics an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.
Financial details of the licensing agreement weren't disclosed.
Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.
In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.
The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.
Shares of Merus were up around 3% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.